指南与共识骨质疏松与代谢性骨病

瑞士抗骨质疏松协会立场声明:HIV感染者的骨脆性诊断、预防与治疗

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.
指南 / 共识 · Osteoporos Int · 2019-01-02

瑞士抗骨质疏松协会发布立场声明,针对HIV感染者骨脆性风险更高且约提前10年出现的特点,基于流行病学和病理生理学现状,提出骨质疏松诊断、预防和管理的共识。声明建议所有HIV患者定期评估骨折风险并采取一般预防措施,绝经后女性、50岁以上男性及有其他临床脆性骨折风险者应进行骨密度测量,算法明确了双膦酸盐治疗及调整抗逆转录病毒治疗方案以选择更亲骨选项的指征。

要点

  • HIV感染者骨折风险更高,且约提前10年出现。
  • 所有HIV患者应定期评估骨折风险并实施一般预防措施。
  • 绝经后女性、50岁以上男性及有其他临床脆性骨折风险者应测量骨密度。

核心结论

  • 基于当前HIV感染者骨质疏松的流行病学和病理生理学现状,瑞士抗骨质疏松协会提供关于该人群骨质疏松诊断、预防和管理最佳实践的共识。

研究设计与样本

  • 瑞士抗骨质疏松协会发布的立场声明,基于当前流行病学和病理生理学现状形成共识。

主要发现

  • HIV感染者骨折风险更高,且约提前10年增加。
  • 经典骨脆性危险因素在HIV感染者中高度流行,HIV感染本身及抗逆转录病毒治疗(三联组合抗逆转录病毒治疗)方案(尤其是替诺福韦和蛋白酶抑制剂)也促进骨丢失。
  • 大部分骨丢失发生在病毒活动期和启动抗逆转录病毒治疗(免疫重建)时,并与骨吸收增加(RANKL上调)相关。
  • 近期数据表明,启动抗逆转录病毒治疗时补充钙和维生素D可降低骨密度丢失。
  • 替诺福韦艾拉酚胺降低替诺福韦血浆浓度可减轻骨密度丢失,但是否有助于降低骨折风险仍未知。

关键数值与推荐

  • 所有HIV患者应定期评估骨折风险,并应实施一般预防措施。
  • 所有绝经后女性、50岁以上男性及有其他临床脆性骨折风险的患者符合骨密度测量指征。
  • 算法明确了何时指示使用双膦酸盐治疗以及审查抗逆转录病毒治疗方案以 favoring 更亲骨选项。

临床怎么用

  • 所有HIV患者应定期评估骨折风险并实施一般预防措施。
  • 绝经后女性、50岁以上男性及有其他临床脆性骨折风险者应进行骨密度测量。
  • 根据算法明确双膦酸盐治疗及调整抗逆转录病毒治疗方案以选择更亲骨选项的指征。

局限性

  • 替诺福韦艾拉酚胺降低替诺福韦血浆浓度可减轻骨密度丢失,但是否有助于降低骨折风险仍未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general population. Accordingly, age-related comorbidities, including osteoporosis, are increasing. Fracture risk is higher and increases approximately 10 years earlier in PLWH. Classical risk factors of bone fragility are highly prevalent in PLWH but factors specific for HIV infection itself and the type of antiretroviral therapy (ART) (triple combination antiretroviral therapy) regimen (especially tenofovir and protease inhibitors) also contribute to bone loss. The majority of bone loss occurs during virus activity and at initiation of ART (immune reconstitution) and is associated with an increase of bone resorption (upregulation RANKL). Recent data indicate that calcium and vitamin D supplements as ART initiation lower BMD loss. The reduction of tenofovir plasma concentrations with tenofovir alafenamide attenuates BMD loss but it remains unknown whether it will contribute to reduce fracture risk. Hence, special considerations for the management of bone fragility in PLWH are warranted. Based on the current state of epidemiology and pathophysiology of osteoporosis in PLWH, we provide the consensus of the Swiss Association against Osteoporosis on best practice for diagnosis, prevention, and management of osteoporosis in this population. Periodic assessment of fracture risk is indicated in all HIV patients and general preventive measures should be implemented. All postmenopausal women, men above 50 years of age, and patients with other clinical risk for fragility fractures qualify for BMD measurement. An algorithm clarifies when treatment with bisphosphonates and review of ART regimen in favour of more bone-friendly options are indicated.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Biver E, Calmy A, Aubry-Rozier B, et al. Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. Osteoporos Int. 2019. PMID: 30603840. doi:10.1007/s00198-018-4794-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。